Table II.

Demographic and clinical data of the anti-HBe positive patients.

				Nucleotides at positions			No. of substitutionsa
Genotype	Patient	Age/Sex	Clinical status	1762-1764	1858	1896	CPMs	UPMs
A	A1	55/M	Cirrhosis	AGG	C	G	0	0
	A2	41/F	Cirrhosis	AGG	C	G	0	0
	A3	45/M	Cirrhosis, HCC	AGG	C	G	0	1
	A4	40/F	Cirrhosis	AGG	C	G	0	0
	A5	10/F	Asymptomatic	TGA (mutant)	C	G	1	6
	A6	52/M	CAH	TGA (mutant)	C	G	1	8
	A7	38/M	CAH	AGG	C	G	0	2
	A8	54/M	Cirrhosis	AGG	C	G	0	0
	A9	52/M	CAH	AGG	C	G	0	4
	A10	39/M	Asymptomatic	AGG	C	G	0	0
D	D1	36/M	CAH	AGG	T	G	0	2
	D2	54/F	Asymptomatic	TGA (mutant)	T	A (stop)	2	7
	D3	56/F	CAH	TGA (mutant)	T	A (stop)	2	13
	D4	35/M	Cirrhosis	TGA (mutant)	T	A (stop)	2	5
	D5	55/M	CAH	TGA (mutant)	T	A (stop)	2	8
	D6	47/M	Asymptomatic	AGG	T	G	0	6
	D7	53/M	Asymptomatic	AGG	T	G	0	6
F	F1	10/M	Asymptomatic	AGG	C	G	0	7
	F2	35/M	CAH	AGG	T	A (stop)	1	8

^aNumber of common (CPMs) and uncommon (UPMs) point mutations (see text) in a 200-bp genome segment, from nt 1720 to nt 1919